Abstract:The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka in 2006 was heralded as a major breakthrough of the decade in stem cell research. The ability to reprogram human somatic cells to a pluripotent embryonic stem cell-like state through the ectopic expression of a combination of embryonic transcription factors was greeted with great excitement by scientists and bioethicists. The reprogramming technology offers the opportunity to generate patient-specific stem cells for modeling human diseases, drug development and screening, and individualized regenerative cell therapy. However, fundamental questions have been raised regarding the molecular mechanism of iPSCs generation, a process still poorly understood by scientists. The efficiency of reprogramming of iPSCs remains low due to the effect of various barriers to reprogramming. There is also the risk of chromosomal instability and oncogenic transformation associated with the use of viral vectors, such as retrovirus and lentivirus, which deliver the reprogramming transcription factors by integration in the host cell genome. These challenges can hinder the therapeutic prospects and promise of iPSCs and their clinical applications. Consequently, extensive studies have been done to elucidate the molecular mechanism of reprogramming and novel strategies have been identified which help to improve the efficiency of reprogramming methods and overcome the safety concerns linked with iPSC generation. Distinct barriers and enhancers of reprogramming have been elucidated, and non-integrating reprogramming methods have been reported. Here, we summarize the progress and the recent advances that have been made over the last 10 years in the iPSC field, with emphasis on the molecular mechanism of reprogramming, strategies to improve the efficiency of reprogramming, characteristics and limitations of iPSCs, and the progress made in the applications of iPSCs in the field of disease modelling, drug discovery and regenerative medicine. Additionally, this study appraises the role of genomic editing technology in the generation of healthy iPSCs.

10th anniversary of iPS cells: the challenges that lie ahead

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications

A decade of transcription factor-mediated reprogramming to pluripotency

Advances in understanding the cell types and approaches used for generating induced pluripotent stem cells

[Progress and potential applications of induced pluripotent stem cell technology]

The Future of Ips Cells in Advancing Regenerative Medicine.

Progress regarding induction of pluripotent stem cells

Induced pluripotent stem cells: status quo and future

The occurrence and development of induced pluripotent stem cells

Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming

Outstanding Questions Regarding Induced Pluripotent Stem (Ips) Cell Research

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

iPS cell therapy 2.0: Preparing for next‐generation regenerative medicine

Inducing Pluripotency in Somatic Cells: Historical Perspective and Recent Advances

Advances in generation of disease-specific induced pluripotent stem (iPS) cells

The Progress of Induced Pluripotent Stem Cells Research in China

FROM TETRAPLOID-COMPLEMENTING MOUSE Ips CELLS TO FULLY PLURIPOTENT PATIENT-SPECIFIC Ips CELLS

Research Progress in Induced Pluripotent Stem Cell Technology

Remodeling of Epigenetic Landscape During Induced Somatic Cell Reprogramming

Roads to Pluripotency